Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction A systematic review and meta-analysis

Human Fertility

Volumn 16, Issue 3, 2013, Pages 168-174

  Baumgarten, Miriam ^a   Polanski, Lukasz ^a   Campbell, Bruce ^a   Raine Fenning, Nick ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Dopamine agonist; OHSS; Prevention; Treatment

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOCARPAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PLACEBO; QUINAGOLIDE; ROPINIROLE; TALIPEXOLE;

DISEASE SEVERITY; HUMAN; INFERTILITY THERAPY; OVARY HYPERSTIMULATION; PREVALENCE; REVIEW; SYSTEMATIC REVIEW;

DOPAMINE AGONISTS; EVIDENCE-BASED MEDICINE; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; REPRODUCTIVE TECHNIQUES, ASSISTED; SEVERITY OF ILLNESS INDEX;

EID: 84884576483     PISSN: 14647273     EISSN: 17428149     Source Type: Journal    
DOI: 10.3109/14647273.2013.833348     Document Type: Review

References (71)

1. Afl atoonian, A., Ghandi, S., & Tabibnejad, N. (2008). Comparison of coasting with Cabergoline administration for prevention of early severe OHSS in ART. Iranian Journal of Reproductive Medicine, 6, 51-55.
2. Ahmadi, Sh., Rahmani, E., & Oskouian, H. (2010). Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome. Reproductive BioMedicine Online, 20, S41-S42.
3. Alhalabi, M., Samawi, S., Taha, A., Kafri, N., Modi, S., Khatib, A., et al. (2011). Quinagolide reduces OHSS in high risk ICSI patients. Abstracts of the 27th Annual Meeting of European Society of Human Reproduction and Embryology, Stockholm, Sweden, 3-6 July 2011. Human Reproduction, 26, P-508.http://humrep. oxfordjournals.org/content/26/suppl-1/i296.full.pdf-html
4. Alvarez, C., Alonso-Muriel, I., Garcia, G., Crespo, J., Bellver, J., Simon, C., & Pellicer, A. (2002). Implantation is apparently unaff ected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Human Reproduction, 22, 3210-3214. (Pubitemid 351696781)
5. Alvarez, C., Mart í-Bonmat í, L., Novella-Maestre, E., Sanz, R., Gomez, R., Fernandez-Sanchez, M., et al. (2007). Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Journal of Clinical Endocrinology and Metabolism, 92, 2931-2937. (Pubitemid 47236352)
6. Ata, B., Seyhan, A., Orhaner, S., & Urman, B. (2009). High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertility and Sterility, 92, 1168.e1-4.
7. Busso, C., Fernandez-Sanchez, M., Garcia-Velasco, J.A., Landeras, J., Ballesteros, A., Munoz, E., et al. (2010). The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Human Reproduction, 25, 995-1004.
8. Carizza, C., Abdelmassih, V., Abdelmassih, S., Ravizzini, P., Salgueiro, L., Salgueiro, P.T., et al. (2008). Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reproductive BioMedicine Online, 17, 751-755.
9. CEMACH. (2007). National Institute for Clinical Excellence, Scottish Executive Health Department, Department of Health, Social Services and Public Safety, Northern Ireland. Saving mother ' s lives; 2003-2005. The seventh report of the confi dential enquiries into maternal deaths in the United Kingdom. London: CEMACH.
10. Ferraretti, A.P., Gianaroli, L., Diotallevi, L., Festi, C., & Trounson, A. (1992). Dopamine treatment for severe ovarian hyperstimulation syndrome. Human Reproduction, 7, 180-183.
11. Gustofson, P.B.R. & Van Nest, K.S. (2005). Aggressive outpatient management of severe ovarian hyperstimulation syndrome avoids complications and prolonged disease course. Fertility and Sterility, 84, S95-S230.
12. Hwang, J.L., Lin, Y.H., & Seow, K.M. (2010). Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients wiThextremely high estradiol levels. International Journal of Gynaecology and Obstetrics, 108, 159-160.
13. Kasum, M. (2010). New insights in mechanisms for development of ovarian hyperstimulation syndrome. Collegium Antropologicum, 34, 1139-1143.
14. Manno, M., Tomei, F., Marchesan, E., & Adamo, V. (2005). Cabergoline: a safe, easy, cheap, and Effective drug for prevention/treatment of ovarian hyperstimulation syndrome European Journal of Obstetrics, Gynecology, and Reproductive Biology, 122, 127-128. (Pubitemid 41265694)
15. Navot, D., Bergh, P.A., & Laufer, N. (1992). Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility, 58, 249-261.
16. Papaleo, E., Doldi, N., De Santis, L., Marelli, G., Marsiglio, E., Rofena, S., & Ferrari, A. (2001). Cabergoline infl uences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Human Reproduction, 16, 2263-2266. (Pubitemid 33054119)
17. Ricci, E., Parazzini, F., Motta, T., Ferrari, CI., Colao, A., Clavenna A, et al. (2002). Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology, 16, 791-793. (Pubitemid 35278500)
18. Rizk, B. & Aboulghar, M. (1991). Modern management of ovarian hyperstimulation syndrome. Human Reproduction, 6, 1082-1087.
19. Robert, E., Musatti, L., Piscitelli, G., & Ferrari, C.I. (1996). Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reproductive Toxicology, 10, 333-337. (Pubitemid 26310263)
20. Rollene, N.L., Amols, M.H., Hudson, S.B.A., & Coddington, C.C. (2009). Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertility and Sterility, 92, 1169. e15-17.
21. Salah Edeen, A.M.R., Alhelou, Y.M. (2009). Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation Comparative study with prednisolone. Abstracts of the 25th Annual Meeting of ESHRE; 28 June-1 July; Amsterdam, The Netherlands.
22. Shaltout, A., Shohayeb, A., Eid, M., & Abbas, S. (2009). Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and Effect on outcome. Abstracts of the 25th Annual Meeting of ESHRE, Amsterdam, The Netherlands, 28 June-1 July 2009. Human Reproduction, 24, O-154.http://humrep.oxfordjournals. org/content/24/suppl-1/i60.full.pdf-html
23. Sherwal, V., Malik, S., & Bhatia, V. (2010). Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction. Journal of Human Reproductive Sciences, 3, 85-90.
24. Shrivastav, P., Nadkarni, P., & Craft, I. (1994). Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Human Reproduction, 9, 812-814. (Pubitemid 24168063)
25. Soares, S.R. (2012). Etiology of OHSS and use of dopamine agonists. Fertility and Sterility, 97, 517-522.
26. Sohrabvand, F., Ansaripour, S., Bagheri, M., Shariat, M., & Jafarabadi, M. (2009). Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients. International Journal of Fertility and Sterility, 3, 35-40.
27. Soliman, B.S. (2011). Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome. Middle East Fertility Society Journal, 16, 56-60.
28. Spitzer, D., Wogatzky, J., Murtinger, M., Zech, M.H., Haidbauer, R., & Zech, N.H. (2011). Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertility and Sterility, 95, 2742-2744.e1.
29. Tang, H., Hunter, T., Hu, Y., Zhai, S.-D., Sheng, X., & Hart, R.J. (2012). Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 2, C D008605.
30. Tsunoda, T., Shibahara, H., Hirano, Y., Suzuki, T., Fujiwara, H., Takamizawa, S., et al. (2003). Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecological Endocrinology, 17, 281-286. (Pubitemid 37083033)
31. van der Linden, M., Buckingham, K., Farquhar, C., Kremer, J.A., & Metwally, M. (2011). Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews, 10, CD009154. doi:10.1002/14651858.
32. CD009154.pub2 prospective, randomized, controlled trial. Human Reproduction, 15, 2292-2296.
33. Goldfarb, J.M. & Desai, N. (2003). Follitropin-alpha versus human menopausal gonadotrophin in an in vitro fertilization program. Fertility & Sterility, 80, 1094-1099. (Pubitemid 37377730)
34. Griesinger, G., Kolibianakis, E.M., Venetis, C., Diedrich, K., & Tarlatzis, B. (2010). Oral contraceptive pretreatment signifi-cantly reduces ongoing pregnancy likelihood in gonadotropinreleasing hormone antagonist cycles: an updated meta-analysis. Fertility & Sterility, 94, 2382-2384.
35. Griesinger, G., Schultze-Mosgau, A., Dafopoulos, K., Schroeder, A., Schroer, A., von Otte, S., et al. (2005). Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRHantagonist multiple-dose protocol. Human Reproduction, 20, 1200-1206. (Pubitemid 40790242)
36. Hompes, P.G.A., Broekmans, F.J., Hoozemans, D.A., & Schats, R. (2008). Effectiveness of highly purifi ed menopausal gonadotrophin vs. recombinant follicle-stimulating hormone in fi rst-cycle in vitro fertilization-intracytoplasmatic sperm injection patients. Fertility & Sterility, 89, 1685-1693. (Pubitemid 351756496)
37. Hughes, E.G., Fedorkow, D.M., Daya, S., Sagle, M.A., Van de Koppel, P., & Collins, J.A. (1992). The routine use of gonadotropinreleasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility & Sterility, 58, 888-896.
38. Huirne, J.A. & Lambalk, C.B. (2001). Gonadotropin-releasinghormone- receptor antagonists. Lancet, 358, 1793-1803.
39. Huirne, J.A., Homburg, R., & Lambalk, C.B. (2007). Are GnRH antagonists comparable to agonists for use in IVF Human Reproduction, 22, 2805-2813. (Pubitemid 351696806)
40. Huirne, J.A., Hugues, J.N., Pirard, C., Fischl, F., Sage, J.C., Pouly, J.L., et al. (2006). Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study. Human Reproduction, 21, 1408-1415. (Pubitemid 44445015)
41. Huirne, J.A., Lambalk, C.B., van Loenen, A.C., Schats, R., Hompes, P.G., Fauser, B.C., & Macklon, N.S. (2004). Contemporary pharmacological manipulation in assisted reproduction. Drugs, 64, 297-322. (Pubitemid 38283045)
42. Humaidan, P., Bungum, M., Bungum, L., & Yding Andersen, C. (2004). Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist downregulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedicine Online, 8, 635-643. (Pubitemid 38744939)
43. Jansen, C.A., van Os, H.C., Out, H.J., & Coelingh Bennink, H.J. (1998). A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients. Human Reproduction, 13, 2995-2999. (Pubitemid 28521838)
44. Keene, J.L., Matzuk, M.M., & Boime, I. ( 1989). Expression of recombinant human choriogonadotropin in Chinese hamster ovary glycosylation mutants. Molecular Endocrinology, 3, 2011-2017. (Pubitemid 20036907)
45. Kilani, Z., Dakkak, A., Ghunaim, S., Cognigni, G.E., Tabarelli, C., Parmegiani, L., & Filicori, M. (2003). A prospective, randomized, controlled trial comparing highly purifi ed hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Human Reproduction, 18, 1194-1199. (Pubitemid 36740563)
46. Kolibianakis, E.M., Venetis, C.A., Kalogeropoulou, L., Papanikolaou, E., & Tarlatzis, B.C. (2011). Fixed versus fl exible gonadotropinreleasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertility & Sterility, 95, 558-562.
47. Larizgoitia, I., Estrada, M.D., & Garcia-Altes, A. (2000). Recombinant FSH as adjuvant in assisted reproduction: some data on the effi cacy and effi ciency of recombinant FSH urinary FSH. Catalan Agency for Health Technology Assessment and Research (CAHTA), 1-16.
48. Levi-Setti, P.E., Cavagna, M., & Bulletti, C. (2006). Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. European Journal of Obstetrics, Gynecology and Reproductive Biology, 126, 212-216. (Pubitemid 43766308)
49. Lisi, F., Rinaldi, L., Fishel, S., Caserta, D., Lisi, R., & Campbell, A. (2005). Evaluation of two doses of recombinant luteinising hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility & Sterility, 83, 309-315. (Pubitemid 40221781)
50. Maheshwari, A., Gibreel, A., Siristatidis, C.S., & Bhattacharya, S. (2011). Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews, 10, CD006919.
51. Marci, R., Caserta, D., Dolo, V., Tatone, C., Pavan, A., & Moscarini, M. (2005). GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reproductive Biomedicine Online, 11, 189-193. (Pubitemid 41086943)
52. Marrs, R., Meldrum, D., Muasher, S., Schoolcraft, W., Werlin, L., & Kelly, E. (2003). Randomized trial to compare the Effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Biomedicine Online, 8, 175-182. (Pubitemid 38208463)
53. Mochtar, M.H., Van der Veen, F., Ziech, M., van Wely, M., & Musters, A. (2007). Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews, 18, CD005070.
54. Nardo, L.G., Fleming, R., Howles, C.M., Bosch, E., Hamamah, S., Ubaldi, F.M., et al. (2011). Conventional ovarian stimulation no longer exists: welcome to the age of individualized ovarian stimulation. Reproductive Biomedicine Online, 23, 141-148.
55. National Collaborating Centre for Women' s and Children' s Health. (2004). Fertility: assessment and management for people with fertility problems. Clinical Guideline. London, UK: RCOG Press.
56. Ng, E.H., Lau, E.Y., Yeung, W.S., & Ho, P.C. (2001). HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial. Human Reproduction, 16, 319-325. (Pubitemid 32149428)
57. Nyboe Andersen, A., Humaidan, P., Fried, G., Hausken, J., Antila, L., Bangsbøll, S., et al. (2008). Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod, 23, 427-434. (Pubitemid 351651237)
58. Pandian, Z., McTavish, A.R., Aucott, L., Hamilton, M.P.R., & Bhattacharya, S. (2010). Interventions for ' poor responders ' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database of Systematic Reviews, 20, CD004379.
59. Rashidi, B.H., Sarvi, F., Tehrani, E.S., Zayeri, F., Movahedin, M., & Khanafshar, N. (2005). The Effect of HMG and recombinant human FSH on oocyte quality: a randomized single-blind clinical trial. European Journal of Obstetrics, Gynecology and Reproductive Biology, 120, 190-194. (Pubitemid 40745323)
60. Sallam, H.N., Garcia-Velasco, J.A., Dias, S., Arici, A., & Abou-Setta, A.M. (2006). Long-term pituitary down-regulation before in vitro fertilization (IVF) for women wiThendometriosis. Cochrane Database of Systematic Reviews, 25, CD004635.
61. Sauer, M.V., Th ornton, M.H. II, Schoolcraft, W., & Frishman, G.N. (2004). Comparative effi cacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online, 9, 487-493. (Pubitemid 39517491)
62. Shoham, Z. (2002). The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertility & Sterility, 77, 1170-1177. (Pubitemid 34626325)
63. Smulders, B., van Oirschot, S.M., Farquhar, C., Rombauts, L., & Kremer, J.A.M. (2010). Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews, 20, CD006109.
64. Strehler, E., Abt, M., El-Danasouri, I., De Santo, M., & Sterzik, K. (2001). Impact of recombinant follicle-stimulating hormone and humanmenopausal gonadotropins on in vitro fertilization outcome. Fertility & Sterility, 75, 332-336. (Pubitemid 32112110)
65. Sullivan, M.W., Stewart-Akers, A., Krasnow, J.S., Berga, S.L., & Zeleznik, A.J. (1999). Ovarian responses in women to recombinant folliclestimulating hormone and luteinizing hormone (LH): a role for LH in the fi nal stages of follicular maturation. Journal of Clinical Endocrinology and Metabolism, 84, 228-232. (Pubitemid 29036707)
66. Tarlatzis, B., Tavmergen, E., Szamatowicz, M., Barash, A., Amit, A., Levitas, E., & Shoham, Z. (2006). The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Human Reproduction, 21, 90-94. (Pubitemid 41794295)
67. Templeton, A. & Morris, J.K. (1998). Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. New England Journal of Medicine, 339, 573-577. (Pubitemid 28385653)
68. Van Den Wijngaard, L., Van Wely, M., Van Voorst, S., Van Mello, N.M., Koks, C.A., Van Der Veen, et al. (2011). Patient ' s preference for GnRH-agonists or GnRH-antagonists in IVF or ICSI-a discrete choice experiment. Human Reproduction, 26, i1-i353.
69. van Wely, M., Kwan, I., Burt, A.L., Thomas, J., Vail, A., Van der Veen, F., & Al-Inany, H.G. (2012). Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Human Reproduction Update, 18, 111.
70. van Wely, M., Westergaard, L.G., Bossuyt, P.M., & van der Veen, F. (2003). Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertility & Sterility, 80, 1086-1093. (Pubitemid 37377729)
71. Westergaard, L.G., Erb, K., Laursen, S.B., Rex, S., & Rasmussen, P.E. (2001). Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotrophic women down-regulated with a gonadotropinreleasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertility & Sterility, 76, 543-549.